18F-PSMA-1007 PET/MR compared to PET/CT in prostate cancer recurrence: impact on clinical management

For patients with suspected prostate cancer recurrence, we examined the added value of 18F-PSMA-1007 PET to MR and CT imaging, and whether choice of PET modality, i.e. PET/MR or PET/CT, had an impact on clinical management. An intention-to-treat analysis was performed using findings from MR and CT alone, MR and CT with PET from PET/CT, and MR and CT with PET from PET/MR. Addition of 18F-PSMA PET changed clinical management in over 40% of patients. Differences in clinical management between PET/CT and PET/MR were smaller than adding any PET modality to MR and CT.